Rishi Shah to head chemistry at Ubiquigent

Ubiquigent Ltd
Appointee name
Rishi Shah

United Kingdom

Rishi Shah, a medicinal chemist, has joined Ubiquigent Ltd as head of chemistry to help progress the company’s deubiquitinase modulators for cancer and other diseases. The technology has application in protein degradation, stabilisation and cellular signalling. Dr Shah joins from GSK Plc where he led development of multiple targeted protein degradation programmes across a range of therapeutic areas. This is in addition to developing an orally bioavailable proteolysis targeting chimera (PROTAC) platform and a bifunctional linker library. Dr Shah obtained his PhD in medicinal chemistry and chemical biology through a programme at the University of Strathclyde in Scotland, supported by GSK.

Ubiquigent announced the appointment on 29 August 2023.

Copyright 2023 Evernow Publishing Ltd.